Short-course tislelizumab with chemoradiation for nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a shorter course of the immunotherapy drug tislelizumab combined with standard chemotherapy and radiation for a specific type of nasopharyngeal cancer. It aims to see if this approach is safe and effective for patients with advanced-stage disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a type of nasopharyngeal cancer called non-keratinizing carcinoma, confirmed by biopsy.
- Your daily activities are not limited (ECOG score 0 or 1).
- Your cancer is at a specific advanced stage (T4N1 or T1-4N2-3 according to the AJCC 9th edition).
- Your blood counts (white cells, hemoglobin, platelets) and liver/kidney function are adequate as determined by blood tests.
- You are not pregnant or breastfeeding and agree to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial tests a combination of focused radiation (SBRT) and two targeted drugs (nimotuzumab and tislelizumab) for people with nasopharyngeal cancer that has come back or spread to a few spots (1-5) after prior immunotherapy. It aims to see if this triple therapy can help control the disease when standard treatment has stopped working.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
This trial tests a combination of an oral targeted therapy (anlotinib) plus immunotherapy and standard chemoradiation for people with high-risk nasopharyngeal cancer. The goal is to see if this approach is more effective than standard treatment.
This trial tests whether a targeted radiation therapy, combined with the immunotherapy drug toripalimab before and after treatment, can reduce side effects while still effectively treating nasopharyngeal cancer. It is for patients with certain tumor sizes or stages who have not had prior neck radiation or immunotherapy.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.